AtorvaStatin Postpartum and Reduction of Cardiovascular risK

Prior treatment

• Individuals who were prescribed an 3-hydroxy-3 methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor prior to or during pregnancy,
• Known familial hypercholesterolemia or pre-existing hyperlipidemia, specifically Low-density Lipoprotein (LDL) \>190 prior to pregnancy or diagnosis of hyperlipidemia with prescription of HMG-CoA reductase inhibitor prior to delivery,

Other illness

• Hypertensive diagnosis thought to be secondary to fetal condition,
• Contraindications to HMG-CoA reductase inhibitor therapy or known hypersensitivity to atorvastatin or any component,
• History of rhabdomyolysis or myopathy,
• Human Immunodeficiency Virus (HIV) positivity, due to potential interactions between atorvastatin and HIV protease inhibitors,
• History of solid organ transplant, due to potential interactions between atorvastatin and immunosuppressants
• Active cancer, or
• Current use of medications with potential drug interactions, namely cyclosporine, clarithromycin, itraconazole, HIV protease inhibitors, rifampin, and digoxin.

Lab values

• Active liver disease (acute hepatitis, chronic active hepatitis, unexplained persistent transaminitis (at least twice upper limit of normal serum transaminases)),

Other

• Breastfeeding for \>= 6 months,
• Plan for pregnancy conception in the next 6 months,
• Incarcerated individuals,

• Postpartum
• ≥ 20 years old with the ability to give informed consent
• Diagnosis of gestational hypertension, preeclampsia prior to delivery admission, or diagnosed with preeclampsia during delivery admission, as determined by clinical team using the American College of Obstetricians and Gynecologists (ACOG) criteria.
• English speaking